These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

703 related articles for article (PubMed ID: 31835074)

  • 1. Assessing the validity of EQ-5D-5L in people with head & neck cancer: Does a generic quality of life measure perform as well as a disease-specific measure in a patient population?
    Davies A; Waylen A; Leary S; Thomas S; Pring M; Janssen B; Beynon R; Lang S; Schimansky S; Hurley K; Ness A
    Oral Oncol; 2020 Feb; 101():104504. PubMed ID: 31835074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping the EORTC QLQ-C30 and QLQ-H&N35, onto EQ-5D-5L and HUI-3 indices in patients with head and neck cancer.
    Noel CW; Stephens RF; Su JS; Xu W; Krahn M; Monteiro E; Goldstein DP; Giuliani M; Hansen AR; de Almeida JR
    Head Neck; 2020 Sep; 42(9):2277-2286. PubMed ID: 32333829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer.
    Hagiwara Y; Shiroiwa T; Taira N; Kawahara T; Konomura K; Noto S; Fukuda T; Shimozuma K
    Health Qual Life Outcomes; 2020 Nov; 18(1):354. PubMed ID: 33143687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the minimally important difference for the EQ-5D-5L and EORTC QLQ-C30 in cancer.
    Bourke S; Bennett B; Oluboyede Y; Li T; Longworth L; O'Sullivan SB; Braverman J; Soare IA; Shaw JW
    Health Qual Life Outcomes; 2024 Sep; 22(1):81. PubMed ID: 39304893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after.
    Miret C; Orive M; Sala M; García-Gutiérrez S; Sarasqueta C; Legarreta MJ; Redondo M; Rivero A; Castells X; Quintana JM; Garin O; Ferrer M;
    Qual Life Res; 2023 Apr; 32(4):989-1003. PubMed ID: 36630024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measuring the Time to Deterioration for Health-Related Quality of Life in Patients With Metastatic Breast Cancer Using a Web-Based Monitoring Application: Longitudinal Cohort Study.
    Brusniak K; Feisst M; Sebesteny L; Hartkopf A; Graf J; Engler T; Schneeweiss A; Wallwiener M; Deutsch TM
    JMIR Cancer; 2021 Oct; 7(4):e25776. PubMed ID: 34636732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "The validity of the EQ-5D-5L in measuring quality of life benefits of breast reconstruction".
    Kouwenberg CAE; Kranenburg LW; Visser MS; Busschbach JJ; Mureau MAM
    J Plast Reconstr Aesthet Surg; 2019 Jan; 72(1):52-61. PubMed ID: 30270015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30.
    van Dongen-Leunis A; Redekop WK; Uyl-de Groot CA
    Value Health; 2016; 19(6):834-843. PubMed ID: 27712712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How Should We Capture Health State Utility in Dementia? Comparisons of DEMQOL-Proxy-U and of Self- and Proxy-Completed EQ-5D-5L.
    Martin A; Meads D; Griffiths AW; Surr CA
    Value Health; 2019 Dec; 22(12):1417-1426. PubMed ID: 31806199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Internal Responsiveness of EQ-5D-5L and EORTC QLQ-C30 in Dutch Breast Cancer Patients during the First Year Post-Surgery: A Longitudinal Cohort Study.
    Vrancken Peeters NJMC; van Til JA; Huberts AS; Siesling S; Husson O; Koppert LB
    Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients.
    Khan I; Morris S; Pashayan N; Matata B; Bashir Z; Maguirre J
    Health Qual Life Outcomes; 2016 Apr; 14():60. PubMed ID: 27072351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30.
    Krabbe PF; Peerenboom L; Langenhoff BS; Ruers TJ
    Qual Life Res; 2004 Sep; 13(7):1247-53. PubMed ID: 15473503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study.
    Hernandez G; Garin O; Dima AL; Pont A; Martí Pastor M; Alonso J; Van Ganse E; Laforest L; de Bruin M; Mayoral K; Serra-Sutton V; Ferrer M;
    J Med Internet Res; 2019 Jan; 21(1):e10178. PubMed ID: 30672744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
    Rischin D; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Braña I; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Ishak WZW; Hong RL; Mendoza RG; Jia L; Chirovsky D; Norquist J; Jin F; Burtness B
    Oral Oncol; 2022 May; 128():105815. PubMed ID: 35381576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping EORTC-QLQ-C30 and QLQ-CR29 onto EQ-5D-5L in Colorectal Cancer Patients.
    Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
    J Gastrointest Cancer; 2020 Mar; 51(1):196-203. PubMed ID: 30977049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer.
    Marriott ER; van Hazel G; Gibbs P; Hatswell AJ
    J Med Econ; 2017 Feb; 20(2):193-199. PubMed ID: 27676291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life in people with advanced dementia: a comparison of EQ-5D-5L and QUALID instruments.
    Sopina E; Chenoweth L; Luckett T; Agar M; Luscombe GM; Davidson PM; Pond CD; Phillips J; Goodall S
    Qual Life Res; 2019 Jan; 28(1):121-129. PubMed ID: 30187395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping the EORTC QLQ-C30 and QLQ-H&N35 to the EQ-5D for head and neck cancer: Can disease-specific utilities be obtained?
    Beck ACC; Kieffer JM; Retèl VP; van Overveld LFJ; Takes RP; van den Brekel MWM; van Harten WH; Stuiver MM
    PLoS One; 2019; 14(12):e0226077. PubMed ID: 31834892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients.
    Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
    Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):89-96. PubMed ID: 30173585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes.
    Catto JWF; Downing A; Mason S; Wright P; Absolom K; Bottomley S; Hounsome L; Hussain S; Varughese M; Raw C; Kelly P; Glaser AW
    Eur Urol; 2021 May; 79(5):621-632. PubMed ID: 33581875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.